Sandrena Product Info

  

For UK healthcare professionals. Prescribing information and adverse event reporting can be found at the bottom of this page.

See SmPC for full information before prescribing

SANDRENA® GEL OVERVIEW:

Indications:1

  • Hormone Replacement Therapy (HRT) for oestrogen deficiency symptoms in postmenopausal women
  • Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis

The experience of treating women older than 65 years old is limited.

High concentration, low volume, body identical, transdermal oestrogen replacement therapy.1

Two strengths available:1

  • 0.5 mg estradiol dose per sachet
  • 1 mg estradiol dose per sachet

Starting estradiol dose based on severity of symptoms:

The usual starting dose is 1.0 mg estradiol (1.0 g gel) daily.

The maximum starting dose is 1.5 mg estradiol (1.5 g gel) daily and the minimum starting dose is 0.5 mg estradiol (0.5 g gel) daily.

Estradiol dose adjustment after 2–3 cycles:

The dosage can be readjusted individually from a maximum of 1.5 mg estradiol per day to a minimum of 0.5 mg, corresponding to 1.5 g (1 g gel sachet + 0.5 g gel sachet) to 0.5 g (0.5 g gel sachet) of gel per day.

For initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration should be used.

Combine with appropriate progestogen to protect the endometrium:

Sandrena® gel can be used for continuous or cyclical treatment.

In patients with an intact uterus, it is recommended to be combined with appropriate progestogen.

It is not recommended to add a progestogen in hysterectomised women, unless there is a previous diagnosis of endometriosis.

A DISCREET AMOUNT OF GEL:

A high concentration gel that requires a lower volume than the equivalent Oestrogel® dose for the usual starting dose1,2*

  • Sandrena® gel (0.1% w/w): 1 g of gel daily (1 sachet containing 1 mg estradiol)
  • Oestrogel® gel (0.06% w/w): 2.5 g of gel daily (2 metered doses containing 1.5 mg estradiol)

Smaller minimum application area vs Oestrogel® for the usual starting dose:*

  • Sandrena® gel (0.1% w/w): 200 cm2 (1 sachet containing 1 mg estradiol)
  • Oestrogel® gel (0.06% w/w): 750 cm2 (2 metered doses containing 1.5 mg estradiol) – area of application should be as large as possible2

Low volume gel means doses small enough to fit in convenient sachets

Postmenopausal osteoporosis: the minimum effective dose is 1.5 g once daily for most patients.1

CONTRAINDICATIONS:

  • Known, past or suspected breast cancer
  • Known or suspected oestrogen-dependent malignant tumours
  • Undiagnosed genital bleeding
  • Untreated endometrial hyperplasia
  • Previous or current venous thromboembolism
  • Known thrombophilic disorders
  • Active or recent arterial thromboembolic disease
  • Acute liver disease, or a history of liver disease as long as liver functions have failed to return to normal
  • Hypersensitivity to active ingredient or excipients
  • Porphyria

SIDE EFFECTS:

During the first few months of treatment, breakthrough bleeding, spotting and breast tenderness or enlargement can occur. These are usually temporary and normally disappear after continued treatment.

The common side effects include:

  • Weight increase or decrease
  • Depression, nervousness and lethargy
  • Headache, dizziness
  • Hot flushes
  • Nausea, vomiting, stomach cramps, flatulence, abdominal pain
  • Rash, pruritis
  • Unscheduled vaginal bleeding or spotting, vaginal discharge, disorder of vulva/vagina, menstrual disorder, breast pain/tension
  • Skin irritation, application site pain, increased sweating, edema

 

 

Download the
‘HOW TO USE PAD’ here.
Click here to watch the
‘HOW TO USE’ video
Download the How to Use Pad Watch the How to Use video

 


*BMS considers Oestrogel® two measures daily and Sandrena® 1 mg sachet a day would be equivalent to the oestrogen in Evorel Sequi, Evorel Conti or Evorel 50 patches.3

References:

  1. Sandrena® gel Summary of Product Characteristics.
  2. Oestrogel® Summary of Product Characteristics.
  3. BMS. HRT preparations and equivalent alternatives. Available at: https://thebms.org.uk/wp-content/uploads/2024/02/15-BMS-TfC-HRT-preparations-and-equivalent-alternatives-JAN2024-B.pdf (Last accessed November 2026)

November 2026 / MAT-GB-DIV-102026-0002